Core Viewpoint - The company received approval from the National Medical Products Administration for clinical trials of HS387 tablets, a selective KIF18A inhibitor aimed at treating advanced solid tumors such as high-grade serous ovarian cancer and non-small cell lung cancer [1] Company Summary - The company has invested approximately 42.41 million RMB in the research and development of HS387 tablets [1]